Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
transcatheter aortic valve replacement
MedTech
Abbott eyes structural heart gains after Boston Scientific exit
CEO Robert Ford said sales of its Navitor TAVR implant have doubled over the past two years, and that the road ahead looks favorable.
Conor Hale
Jul 17, 2025 1:00pm
Boston Scientific pulls Acurate TAVR implants from market
May 28, 2025 11:01am
FDA approves Edwards TAVR for patients before they show symptoms
May 1, 2025 12:56pm
Edwards highlights 8-year durability data for its Resilia valves
Apr 18, 2025 11:30am
Abbott completes first-in-human balloon-expanded TAVR procedures
Nov 25, 2024 1:30pm
TCT: Boston Scientific's TAVR implant fails head-to-head study
Oct 30, 2024 11:55am
